WEST PHARMACEUTICAL SERVICES, INC.

West Pharmaceutical Services, Inc. specializes in the design, development, and manufacturing of advanced drug delivery systems and packaging solutions for pharmaceutical and biotech applications. Their core capabilities encompass primary packaging components such as rubber stoppers, plungers, and elastomeric closures, as well as secondary packaging and device integration for injectable therapeutics. The company brings deep expertise in elastomer chemistry, sterile manufacturing processes, and aseptic filling technologies, ensuring compliance with cGMP and USP <661> standards. Key differentiators include proprietary polymer formulations, automated inspection systems for particle control, and validated sterilization protocols that support complex biologics and specialty drug formulations. Their technical proficiency extends to compatibility testing, extractables and leachables studies, and closed-system containment solutions for high-potency compounds. Award history is not available to confirm specific agency engagements or contract performance. As a result, no definitive patterns of government work can be inferred from the provided data. The company operates primarily within the broader pharmaceutical manufacturing sector, with its principal activities aligned to NAICS 326299 — Other Plastic Product Manufacturing. In practice, this translates to precision-engineered components for controlled-release systems, prefilled syringes, and inhalation delivery devices used in regulated medical environments. Their market positioning is centered on high-reliability, low-particulate packaging solutions critical to injectable and biologic drug supply chains. West Pharmaceutical Services, Inc. is a multi-location enterprise structured as a 2L entity, headquartered in Exton, Pennsylvania. The company holds no active government certifications. While its primary operations are based in the U.S., its manufacturing and R&D footprint supports global pharmaceutical supply networks. The firm is positioned as a Tier-1 supplier to commercial pharmaceutical manufacturers, with no discernible government contracting activity reflected in the available data.